TCR2 Therapeutics Inc. Stock Predictions

NASDAQ Stock Exchange > Healthcare > Biotechnology

Open Broker Account

$1.48

+0 (+0%)

At Close: Aug 30, 2023

Currently predicting for Mon, 29 Apr 2024

TCRR Predictions History

BE THE FIRST TO PREDICT

The excellent way of becoming a better trader

Easy to use
Enhance your skills
Predict as many as you like
Request predictions
Gather points

Learn to time your buy and sells

I wonder how good you are and if you can beat me?

Now it is your turn to become professional by doing what professionals do - Exercise

Best regards,

Jim - Co-founder of StockInvest.us [ See tutorial video ]

About TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal... TCRR Profile

Golden Star

Ticker	Date	Change	Price
DHT	Apr 24	2.04%	$11.28
MLI	Apr 19	9.66%	$52.28
LPLA	Apr 19	1.42%	$262.59
DOOR	Apr 18	0.167%	$131.39
LNG	Apr 17	1.49%	$156.81
FCN	Apr 16	1.80%	$207.62
ELV	Apr 16	5.97%	$506.97
AKR	Apr 05	4.78%	$16.53
ITCI	Apr 05	7.04%	$68.44
VSTS	Apr 04	0.425%	$18.82

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Sign In